A Case of EBV-Negative Aggressive NK-cell Leukemia: Use of Next-Generation Sequencing in Demystifying a Diagnostic Dilemma and Guiding Clinical Care

Vanessa E. Kennedy(Palo Alto University), Bita Fakhri(University of California, San Francisco), Robert S. Ohgami(University of California, San Francisco), Parul Bhargava(Beth Israel Deaconess Hospital), Kwun Wah Wen(University of California, San Francisco), Diwash Jangam(Stanford University), Neil Dunavin(University Medical Center), Weiyun Z. Ai(City College of San Francisco), Roberto Ruiz‐Cordero(The University of Texas MD Anderson Cancer Center)
Clinical Lymphoma Myeloma & Leukemia
February 27, 2021
10.1016/j.clml.2021.02.010
Cited by 1

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
|Journal of Clinical Oncology|2010|487
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|456
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
|The Lancet Oncology|2021|428
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396